| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 18182322
[patent_doc_number] => 20230043051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA
[patent_app_type] => utility
[patent_app_number] => 17/771275
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771275
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/771275 | ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA | Oct 22, 2020 | Abandoned |
Array
(
[id] => 18565700
[patent_doc_number] => 20230256027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => Use of Liver Progenitor or Stem Cells, Lysates Thereof, and/or Conditioned Medium in Disorders Characterized by Vascular Hyperpermeability
[patent_app_type] => utility
[patent_app_number] => 17/766527
[patent_app_country] => US
[patent_app_date] => 2020-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766527
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766527 | Use of Liver Progenitor or Stem Cells, Lysates Thereof, and/or Conditioned Medium in Disorders Characterized by Vascular Hyperpermeability | Oct 7, 2020 | Abandoned |
Array
(
[id] => 17913512
[patent_doc_number] => 20220315907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => SPLIT CRISPR NUCLEASE TETHERING SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/639022
[patent_app_country] => US
[patent_app_date] => 2020-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639022
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/639022 | SPLIT CRISPR NUCLEASE TETHERING SYSTEM | Sep 30, 2020 | Abandoned |
Array
(
[id] => 17830452
[patent_doc_number] => 20220267756
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX
[patent_app_type] => utility
[patent_app_number] => 17/754050
[patent_app_country] => US
[patent_app_date] => 2020-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754050
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/754050 | COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX | Sep 21, 2020 | Pending |
Array
(
[id] => 18019141
[patent_doc_number] => 20220370640
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP
[patent_app_type] => utility
[patent_app_number] => 17/753768
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753768 | GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP | Sep 17, 2020 | Pending |
Array
(
[id] => 18020944
[patent_doc_number] => 20220372443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => LBM, CPC, OPC, PRODUCTION AND QUALITY CONTROL METHODS THEREFOR, KIT, GRAFT MATERIAL, AND DISEASE MODEL
[patent_app_type] => utility
[patent_app_number] => 17/761518
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761518
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/761518 | LBM, CPC, OPC, PRODUCTION AND QUALITY CONTROL METHODS THEREFOR, KIT, GRAFT MATERIAL, AND DISEASE MODEL | Sep 17, 2020 | Pending |
Array
(
[id] => 18019141
[patent_doc_number] => 20220370640
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP
[patent_app_type] => utility
[patent_app_number] => 17/753768
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753768 | GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP | Sep 17, 2020 | Pending |
Array
(
[id] => 18021022
[patent_doc_number] => 20220372521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => RNA-GUIDED DNA INTEGRATION AND MODIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/634759
[patent_app_country] => US
[patent_app_date] => 2020-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634759
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/634759 | RNA-GUIDED DNA INTEGRATION AND MODIFICATION | Aug 13, 2020 | Abandoned |
Array
(
[id] => 18752502
[patent_doc_number] => 20230355759
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16
[patent_app_type] => utility
[patent_app_number] => 17/597968
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597968
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/597968 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | Jul 30, 2020 | Pending |
Array
(
[id] => 18077720
[patent_doc_number] => 20220403332
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => SELF-ORGANIZING NEURAL ECTODERMAL LINEAGE CELLULAR STRUCTURES, AND COMPOSITIONS AND METHODS RELATING THERETO
[patent_app_type] => utility
[patent_app_number] => 17/621328
[patent_app_country] => US
[patent_app_date] => 2020-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/621328 | SELF-ORGANIZING NEURAL ECTODERMAL LINEAGE CELLULAR STRUCTURES, AND COMPOSITIONS AND METHODS RELATING THERETO | Jun 21, 2020 | Pending |
Array
(
[id] => 17720769
[patent_doc_number] => 20220213489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => CD33 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CD33 POSITIVE MALIGNANCIES
[patent_app_type] => utility
[patent_app_number] => 17/614233
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614233
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/614233 | CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies | May 31, 2020 | Issued |
Array
(
[id] => 17720714
[patent_doc_number] => 20220213434
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => MODIFIED PLURIPOTENT CELLS
[patent_app_type] => utility
[patent_app_number] => 17/607841
[patent_app_country] => US
[patent_app_date] => 2020-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -116
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607841
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607841 | MODIFIED PLURIPOTENT CELLS | May 8, 2020 | Pending |
Array
(
[id] => 17776876
[patent_doc_number] => 20220243225
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
[patent_app_type] => utility
[patent_app_number] => 17/606635
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606635
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/606635 | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS | Apr 28, 2020 | Abandoned |
Array
(
[id] => 16628969
[patent_doc_number] => 20210047622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => METHOD FOR OBTAINING AN ANIMAL MODEL FROM CONDITIONALLY REPROGRAMMED CELLS AND USE OF THE ANIMAL MODEL FOR SCREEING ANTI-TUMOR DRUGS
[patent_app_type] => utility
[patent_app_number] => 17/046981
[patent_app_country] => US
[patent_app_date] => 2019-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046981
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046981 | METHOD FOR OBTAINING AN ANIMAL MODEL FROM CONDITIONALLY REPROGRAMMED CELLS AND USE OF THE ANIMAL MODEL FOR SCREEING ANTI-TUMOR DRUGS | Mar 18, 2019 | Pending |